We're all different. But when we visit the doctor, our treatments are often the same. We think one day health care should be tailored for you. This is called precision medicine. And research can help us get there. Taking part in the All of Us Research Program involves sharing information about your health, habits, and what it's like where you live. If you are 18 or older and live in the United States, you may be able to take part!

The goal of the study is to understand why teams perform better than individuals. In the study, participants will work in small groups of 2-4 members to solve a simple logic puzzle. It is a fun and engaging study to explore why teams perform better than individuals. If you are a student at UNC and 18 years or older, you may be able to take part.

Have you been diagnosed with Metastatic Castration-Resistant Prostate Cancer. If so, you may be able to take part in a research study looking at the safety of giving Docetaxel vs Docetaxel and Radium-223 to patients.

Have you been diagnosed with uterine cancer called endometrial serous carcinoma or carcinosarcoma? If so, you may be able to take part in a research study to test if adding a drug or drugs that target HER2 proteins in addition to the usual combination of chemotherapy drugs could prevent your cancer from returning or shrink your cancer.

Are you receiving initial treatment for non-small cell lung cancer or invasive squamous cell carcinoma of the head and neck and want to participate in research that aims to improve treatment and care of future patients with the same diagnosis? If so, you may be able to participate in a study for an investigational blood test to predict whether your cancer will come back.

Do you have known or suspected lung and/or head and neck cancer? Are you scheduled for a tumor biopsy? If so, you may be able to participate in a research registry aimed at learning more about lung and head/neck cancer.

In this study, we want to learn more about the safety and effectiveness of using a personalized vaccine with a drug called pembrolizumab for the treatment of non‐small cell lung cancer (NSCLC) and squamous cell cancer of the head and neck (SCCHN).

We are doing a study to help us adapt a physical activity program for adults with intellectual disabilities. We are looking for adults with intellectual disabilities, parents/caregivers, support staff, and exercise professionals to complete a survey and take part in interviews or focus groups to provide feedback on a physical activity program. The program includes weekly group fitness meetings, one-to-one coaching meetings, and an app to support setting, monitoring, and achieving exercise goals.

People with SCLC are usually treated with a combination of drugs that are approved by the Food and Drug Administration (FDA). However, these drugs may no longer be working in controlling your cancer or may not be a good treatment option for you. This study uses an investigational combination of drugs, trilaciclib and lurbinectedin. The purpose of this study is to test whether trilaciclib helps minimize the side effects of lurbinectedin and therefore improve the safety of lurbinectedin for the treatment of small cell lung cancer (SCLC).

Are you between 18 and 45 years of age and diagnosed with multiple sclerosis, without MS relapses within the past year? Are you currently prescribed with MS medication? If so, you may be able to participate in a research study examining whether a switch to a high-efficacy medication- Ofatumumab, would work better for you than your current treatment.